Ryuko K, Iwanari O, Nakayama S, Iida K, Kitao M
Department of Obstetrics and Gynecology, Shimane Medical University, Izumo, Japan.
Cancer. 1992 May 1;69(9):2368-78. doi: 10.1002/1097-0142(19920501)69:9<2368::aid-cncr2820690927>3.0.co;2-2.
The serum levels of sialosyl-alpha 2,6GalNAc alpha 1-0-serine/threonine (S-Tn) antigen and CA 125 antigen were measured in 205 patients with gynecologic tumors, including 48 ovarian cancers, 20 endometrial cancers, 29 cervical cancers, 57 benign ovarian tumors, 37 uterine leiomyomas, and 14 adenomyosis. Using a cutoff value of 41 U/ml for S-Tn and 35 U/ml for CA 125, positive findings were obtained in ovarian cancers in 31 of 48 (64.6%) patients with S-Tn antigen, and in 36 of 48 (75%) patients with CA 125. In uterine malignancies, positive findings were obtained in 11 of 49 (22.4%) patients and in 8 of 49 (16.3%) patients with the serum S-Tn and CA 125 antigens, respectively. In ovarian benign tumors, false-positive findings with CA 125 were observed in 16 of 57 (28.1%) patients, but with S-TN antigen in only 3 of 57 (5.3%) patients (P less than 0.01). For the ovarian tumors, excluding patients with recurrent disease, the specificity, positive predictive value, and accuracy of the serum S-Tn antigen level for detecting cancer exceeded that of the serum CA 125. The combined assay of serum S-Tn and CA 125 antigens gave positive results in 38 of 48 (79.2%) patients with ovarian cancers; most of the negative findings were obtained in Stage I disease. A significant decreases in serum S-Tn level was observed after cytoreductive surgery in 14 patients with ovarian cancer (P less than 0.01). Four patients with a subsequent recurrence showed a concomitant rise in serum S-Tn. The cyst fluid and ascitic fluid showed high levels of S-Tn antigen in patients with ovarian cancer, in contrast to findings in patients with benign ovarian tumors. In conclusion, serum S-Tn antigen has limited use in diagnosing early stage ovarian cancer and uterine malignancies, but it can detect with accuracy ovarian cancers when used in a combination assay with CA 125 and can monitor the status of disease after therapy.
对205例妇科肿瘤患者检测了唾液酸基-α2,6- N -乙酰半乳糖胺α1- O -丝氨酸/苏氨酸（S-Tn）抗原和CA 125抗原的血清水平，其中包括48例卵巢癌、20例子宫内膜癌、29例宫颈癌、57例卵巢良性肿瘤、37例子宫肌瘤和14例子宫腺肌病。以S-Tn的临界值41 U/ml和CA 125的临界值35 U/ml计算，48例卵巢癌患者中，S-Tn抗原检测阳性者31例（64.6%），CA 125检测阳性者36例（75%）。在子宫恶性肿瘤患者中，血清S-Tn和CA 125抗原检测阳性者分别为49例中的11例（22.4%）和8例（16.3%）。在卵巢良性肿瘤患者中，57例中有16例（28.1%）CA 125检测出现假阳性结果，而S-TN抗原检测假阳性仅57例中的3例（5.3%）（P<0.01）。对于卵巢肿瘤，排除复发患者后，血清S-Tn抗原水平检测癌症的特异性、阳性预测值和准确性超过血清CA 125。血清S-Tn和CA 125抗原联合检测时，48例卵巢癌患者中有38例（79.2%）呈阳性结果；大多数阴性结果出现在Ⅰ期疾病患者中。14例卵巢癌患者在肿瘤细胞减灭术后血清S-Tn水平显著下降（P<0.01）。4例随后复发的患者血清S-Tn随之升高。与卵巢良性肿瘤患者的结果相反，卵巢癌患者的囊液和腹水显示高水平的S-Tn抗原。总之，血清S-Tn抗原在早期卵巢癌和子宫恶性肿瘤诊断中的应用有限，但与CA 125联合检测时可准确检测卵巢癌，并可监测治疗后疾病状态。
